Novo Nordisk Cuts US List Prices for Ozempic and Wegovy
In a significant move for the pharmaceutical market, Novo Nordisk has announced plans to substantially reduce the list prices of its popular medications, Ozempic and Wegovy. The Denmark-based company aims to slash these prices by up to 50%, bringing them down to $675 per month by January 1, 2027. This change aims to improve access for patients struggling with high out-of-pocket expenses for these drugs.
Details of the Price Cuts
The planned price reduction will impact both Wegovy, a weight-loss medication, and Ozempic, used for diabetes management, along with oral formulations like Rybelsus. Current costs for Wegovy will be halved, while Ozempic prices will see a reduction of approximately one-third.
Market Impact and Competitors
This pricing strategy also reflects a competitive edge against Eli Lilly, a key player in the GLP-1 drug sector. Eli Lilly produces Mounjaro and Zepbound, which are also tailored for weight loss and glucose regulation, respectively. According to TD Cowen, the entire GLP-1 market is expected to grow significantly, potentially reaching $139 billion by 2030.
Aiming for Affordability
Novo Nordisk has indicated that the price adjustments are designed to help those with high-deductible plans or co-insurance commitments related to list prices. While exact figures on current patient expenditures remain unspecified, the company projects that under the new pricing model, costs for insured individuals could drop to as low as $25 per month.
Cash Prices and Medicare Negotiations
Existing cash prices, which span from $149 to $499 per month depending on the drug and dosage, will remain unchanged. Discounts available through the federal TrumpRx site also will not be affected. Notably, this timing aligns with new Medicare pricing negotiations, wherein the future 30-day supply of Ozempic and Wegovy will be priced at $274, significantly lower than the projected new list prices.
Market Reactions
The announcement has already had an effect on stock prices. Shares of both Novo Nordisk and Eli Lilly saw declines following the news, as reported by MarketWatch.
